Dual Approaches for Parkinson’s Disease: Role of the Dopaminergic and Non-Dopaminergic Therapies

Introduction: Parkinson's Disease (PD) is a progressive neurodegenerative disorder characterized by both motor and non-motor symptoms, primarily due to the degeneration of dopaminergic neurons. This review aims to explore the therapeutic landscape of PD, focusing on dopaminergic and non-dopaminergic treatment strategies, as well as recent advancements and future directions in managing the disease. Methods: A comprehensive literature review was conducted using databases such as PubMed, Science Direct, and Scopus, covering studies published up to 2025. The review focused on epidemiological trends, pathophysiological mechanisms, diagnostic approaches, and pharmacological and non-pharmacological therapies related to PD. Results: PD affects approximately 1-2% of individuals over 60 years of age, with its prevalence expected to rise globally. Motor symptoms such as bradykinesia, rigidity, and tremor are wellrecognized, but non-motor symptoms remain underdiagnosed. Dopaminergic therapies, including levodopa and dopamine agonists, are effective in symptom management but are associated with long-term complications. Non-dopaminergic approaches, such as MAO-B inhibitors, amantadine, anticholinergics, and deep brain stimulation, offer additional symptom control. Emerging strategies include gene therapy, immunotherapy, and neuroprotective agents targeting disease modification. Discussion: While current treatments provide symptomatic relief, they do not halt disease progression. A multidimensional therapeutic approach combining dopaminergic and nondopaminergic strategies is necessary. Advances in molecular genetics and biomarker discovery hold promise for early diagnosis and personalized treatment. However, the need for more targeted, disease-modifying therapies remains a major challenge. Conclusion: This review underscores the importance of integrating traditional and emerging therapies for comprehensive PD management. Future research should focus on genetic insights, early detection, and innovative therapeutics to improve patient outcomes and quality of life.